| Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model I Smets, M Versteegh, S Huygens, B Wokke, J Smolders Multiple Sclerosis Journal, 13524585241258692, 2024 | | 2024 |
| Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions A de Boer, AMR van den Bosch, NJ Mekkes, NL Fransen, ... Acta Neuropathologica 147 (1), 1-21, 2024 | | 2024 |
| Twin study dissects CXCR3+ memory B cells as non-heritable feature in multiple sclerosis F Ingelfinger, KL Kuiper, C Ulutekin, L Rindlisbacher, S Mundt, LA Gerdes, ... Med 5 (4), 368-373. e3, 2024 | | 2024 |
| Profiling of microglia nodules in multiple sclerosis reveals propensity for lesion formation AMR van den Bosch, M van der Poel, NL Fransen, MCJ Vincenten, ... Nature communications 15 (1), 1667, 2024 | 2 | 2024 |
| Differential Runx3, Eomes, and T‐bet expression subdivides MS‐associated CD4+ T cells with brain‐homing capacity C Hoeks, F Puijfelik, SC Koetzier, J Rip, CEA Corsten, AF Wierenga‐Wolf, ... European Journal of Immunology 54 (2), 2350544, 2024 | 1 | 2024 |
| CD4+ Trm sustain the chronic phase of auto-immune neuroinflammatory disease A Pignata, D Frieser, CC Hsiao, HJ Engelenburg, M Alis, ... bioRxiv, 2024.03. 26.586880, 2024 | | 2024 |
| BRAIN COMMUNICATIONS F van Puijfelik, KM Blok, RAMK Kranenbarg, J Rip, J de Beukelaar, ... | | 2024 |
| Ocrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosis F van Puijfelik, KM Blok, RAM Klein Kranenbarg, J Rip, J de Beukelaar, ... Brain communications 6 (1), fcae021, 2024 | | 2024 |
| Real‐world challenges in the diagnosis of primary progressive multiple sclerosis KM Blok, J Smolders, J van Rosmalen, CO Martins Jarnalo, B Wokke, ... European Journal of Neurology 30 (12), 3799-3808, 2023 | | 2023 |
| Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model CEA Corsten, SA Huygens, MM Versteegh, BHA Wokke, I Smets, ... Multiple Sclerosis and Related Disorders 80, 105100, 2023 | 4 | 2023 |
| Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis KM Blok, J van Rosmalen, N Tebayna, J Smolders, B Wokke, ... Frontiers in Neurology 14, 1277477, 2023 | | 2023 |
| Normal appearing white matter and early lesion formation in MS J Smolders MULTIPLE SCLEROSIS JOURNAL 29, 5-5, 2023 | | 2023 |
| The propensity of B cells to infiltrate the MS brain: impact of genetic variation and environment L Bogers, J Rip, K Kuiper, J van Langelaar, L Rijvers, S Koetzier, ... MULTIPLE SCLEROSIS JOURNAL 29, 35-36, 2023 | | 2023 |
| A potential biomarker based approach to MS disease classification K Blok, B Wokke, K Ananth, L Giannini, J de Beukelaar, H Seelaar, ... MULTIPLE SCLEROSIS JOURNAL 29, 567-567, 2023 | | 2023 |
| A new genetic variant associated with age-related multiple sclerosis severity associates with enhanced lesion activity and axonal damage J Engelenburg, A Van den Bosch, A Chen, D Wever, J Hamann, I Huitinga, ... MULTIPLE SCLEROSIS JOURNAL 29, 64-64, 2023 | | 2023 |
| Patient-reported outcome measures in discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS): results of a multicenter randomized … E Coerver, WH Fung, J de Beukelaar, W Bouvy, L Canta, O Gerlach, ... MULTIPLE SCLEROSIS JOURNAL 29, 1106-1107, 2023 | | 2023 |
| Discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS): an early-terminated multicenter randomized controlled trial E Coerver, WH Fung, J de Beukelaar, W Bouvy, L Canta, O Gerlach, ... MULTIPLE SCLEROSIS JOURNAL 29, 76-77, 2023 | 3 | 2023 |
| Ocrelizumab treatment associates with reduced CD20dim T cells in the cerebrospinal fluid of people with primary progressive MS F Van Puijfelik, K Blok, RK Kranenbarg, J Rip, J De Beukelaar, ... MULTIPLE SCLEROSIS JOURNAL 29, 594-594, 2023 | | 2023 |
| Broad perilesional rim of macrophages/microglia as biomarker for rapid MS disease progression L Klotz, J Smolders, J Lehto, M Matilainen, A Van den Bosch, L Airas, ... MULTIPLE SCLEROSIS JOURNAL 29, 18-19, 2023 | | 2023 |
| Utility and Implementation of a Federated Research Infrastructure to Assess Lack of Disease Stability as a Real-World Surrogate of PIRA, by Combining MS Clinical Trial and Real … J Oh, J Smolders, F Buijs, R Pedotti, F Dahlke, L Kaczmarek, A Kemmisetti, ... MULTIPLE SCLEROSIS JOURNAL 29, 758-758, 2023 | | 2023 |
Jacobus FA JansenAssociate Professor, Dept. of Radiology, Mental Health & Neuroscience Research Institute, UM & TU/e在 mumc.nl 的电子邮件经过验证
Jacobus FA JansenAssociate Professor, Dept. of Radiology, Mental Health & Neuroscience Research Institute, UM & TU/e在 mumc.nl 的电子邮件经过验证